no code implementations • 1 Feb 2024 • Marta Varela-Eirin, Adrian Varela-Vazquez, Amanda Guitian-Caamano, Carlos Luis Paino, Virginia Mato, Raquel Largo, Trond Aasen, Arantxa Tabernero, Eduardo Fonseca, Mustapha Kandouz, Jose Ramon Caeiro, Alfonso Blanco, Maria D. Mayan
These findings support the use of Cx43 as an appropriate therapeutic target to halt OA progression and to promote cartilage regeneration.